Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

RNA

  • Home
  •  
  • RNA



  • Most Read
  • Latest Comments
  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    Bioxyne leads the way as Australia’s first manufacturer of pharmaceutical cannabis gummies
    • News

  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    INOVIQ validates exosome therapy to target and kill breast cancer cells
    • News

  • Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    Argenica completes production of brain stroke drug, prepares for Phase 2 trial
    • News

  • INOVIQ teams up with ResearchDx for improved cancer biomarker detection
    INOVIQ teams up with ResearchDx for improved cancer biomarker detection
    • News

  • All eyes on PYC as it doses first patient for eye disease trial
    All eyes on PYC as it doses first patient for eye disease trial
    • News

  • INOVIQ validates exosome therapy to target and kill breast cancer cells
    • News

    INOVIQ validates exosome therapy to target and kill breast cancer cells

    About 57 people are diagnosed with breast cancer every day in Australia, with instances having grown over the past decade. New and improved treatments are crucial, and to address that, Australian diagnostics company INOVIQ (ASX: IIQ) has developed a special exosome therapy that can target and kill breast cancer cells in lab tests. The Company

    Read More
    Public
  • All eyes on PYC as it doses first patient for eye disease trial
    • News

    All eyes on PYC as it doses first patient for eye disease trial

    Eye health has been in and out of sight and mind for some time now, urging organisations to demand greater investment and attention towards Aussies’ unmet needs. In 2018, 93% of Aussies aged over 65 reported vision disorders, and the pandemic did little to help by not being a sight for sore eyes. If that

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.